The drug cocktail includes Braftovi, Eli Lilly’s Erbitux and the chemo regimen mFOLFOX6. In patients with metastatic colorectal cancer harboring a BRAF V600E mutation, the combo not only staved ...

Pfizer’s metastatic colorectal cancer (mCRC) combination therapy has met one of the primary endpoints of improving progression-free survival (PFS) in a Phase III trial, further supporting a full ...

Patients with BRAF V600E-mutated metastatic colorectal cancer experienced improved responses when treated with Braftovi plus Erbitux and mFOLFOX6.

The new results from the BREAKWATER study – which is testing the combination of BRAF inhibitor Braftovi (encorafenib) with Eli Lilly's Erbitux (cetuximab) and chemotherapy – showed a ...

Pfizer has been granted FDA approval for BRAFTOVI® in combination with cetuximab and mFOLFOX6 for the treatment of metastatic colorectal cancer with a BRAF V600E mutation. These are among the ...

Dr. Scott Kopetz discusses the BREAKWATER trial investigating Braftovi and Erbitux plus chemo in those with BRAF V600E+ metastatic colorectal cancer. Among patients with BRAF V600E-mutant metastatic ...

Pfizer (PFE) announced positive topline results from the progression-free survival – PFS – analysis of the Phase 3 BREAKWATER study of Braftovi ...

At the time of the ORR analysis, the safety profile of BRAFTOVI in combination with cetuximab and mFOLFOX6 continued to be consistent with the known safety profile of each respective agent.

Of patients on Braftovi plus cetuximab and mFOLFOX6, 22.4% (n=15) had a response lasting 12 months or longer, compared to 11.4% (n=5) with chemotherapy with or without bevacizumab.

The BREAKWATER trial was designed to evaluate Braftovi with Eli Lilly’s (NYSE:LLY) colorectal cancer therapy ERBITUX, with or without another cancer regimen called mFOLFOX6 in newly diagnosed ...